Gene targeting effects by topo i somerase inhibitors using plasma free DNA in patients with SCLC

点击翻译按钮获取中文摘要

Lung cancer is the leading cause of cancer death, and approximately 15% of all lung cancer patients have small-cell lung cancer (SCLC). Although second-line chemotherapy can produce tumor regression, the prognosis is poor. Amrubicin hydrochloride (AMR) is a synthetic anthracycline anticancer agent and a potent topoisomerase II inhibitor. With its predictable and manageable toxicities, AMR is one of the most attractive agents for the treatment of chemotherapy- sensitive and -refractory relapsed SCLC. I reviewed the applicability of AMR therapy for patients with SCLC on Clinical Medicine Insights Oncology 2011. These clinical trials, including phase III studies, will clarify the status of AMR in the treatment of SCLC.